The Chumakov Center plans to double the production of the KoviVac coronavirus vaccine from October 2021 to 2.5 million doses per month. This was stated by the director of the center Aydar Ishmukhametov, transfers Interfax.
The director of the center added that now work is underway to expand production, and everything will be finalized at the end of September. The center received vaccine reactors two weeks ago.
Earlier today Ishmukhametov said that the Center. Chumakova is modifying her vaccine for new strains of coronavirus, including to use it against the “delta”. At the same time, he urged Russians not to wait for new drugs to appear and to be vaccinated with already registered ones.
KoviVac is the third COVID-19 vaccine registered in Russia. For the first time, the drug became available in Moscow at the beginning of summer, however, due to its small amount, many did not have time to graft on them. Already at the end of June, the authorities suspended vaccination with KoviVac. The popularity of the drug is explained by the fact that, unlike Sputnik V and EpiVacCorona, KoviVac was created according to the classical scheme, that is, it uses viruses that have lost the ability to infect cells. The medicine is recommended for those for whom other vaccinations are contraindicated.
Another drug, “EpiVacCorona”, is a vaccine from the Novosibirsk center “Vector”, which, according to rumors widely spread in Russia, should be “softer” than “Sputnik”. At the same time, the volunteers participating in the research really not found they have side effects, although they did not find the necessary antibodies either, and the former employees of “Vector” announced falsification of the data.